Navigation Links
Shire announces publication of open-label study on coadministration of INTUNIV with stimulants
Date:11/16/2009

PHILADELPHIA November 16, 2009 Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV (guanfacine) Extended-Release Tablets published in the October Journal of Child and Adolescent Psychopharmacology. In this open-label safety study, there was no evidence of unique adverse effects with the combination of INTUNIV and amphetamine or methylphenidate relative to what was observed with either medication alone. The open-label study also assessed improvement of Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms using the ADHD Rating Scale-IV (ADHD-RS-IV). INTUNIV is a nonscheduled, once-daily selective alpha-2A agonist indicated for monotherapy treatment of ADHD in children and adolescents ages 6 to 17.

"Pivotal studies have shown that INTUNIV improved ADHD symptoms in children and adolescents with the disorder, and the publication of these safety data gives us insight into administering INTUNIV in combination with stimulant medications in the management of ADHD," said Andrew J Cutler, MD, courtesy assistant professor, department of psychiatry, University of Florida, and CEO and medical director, Florida Clinical Research Center, Bradenton, FL. "This study helped inform the design of a controlled coadministration trial of INTUNIV with stimulant medications, which Shire is currently conducting."

An estimated 25 to 30 percent of ADHD patients may not respond to the most commonly prescribed ADHD medications, methylphenidates and amphetamines, when used alone as ADHD treatment.

About the Coadministration Study

This nine-week, open-label, multicenter, dose-escalation study assessed the safety and effectiveness of coadministering INTUNIV with stimulant medications (methylphenidate or amphetamine). The enrolled patient population included 75 children and adolescents ages 6 to 17 diagnosed with ADHD whose ADHD symptoms were suboptimally co
'/>"/>

Contact: Matt Cabrey
mcabrey@shire.com
484-595-8248
Porter Novelli
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Shire reports analysis examining emotional lability in children with ADHD taking Vyvanse
2. Shire Reports Findings From an Analysis Examining Emotional Lability in Children With ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII
3. Anthem Blue Cross and Blue Shield in New Hampshire Announces Decision to Cover H1N1 Vaccine Administration
4. Yorkshire and Humber NHS Procurement Hub Selects BigHand Voice Platform
5. Anthem Blue Cross and Blue Shield in New Hampshire, Elliot Hospital Announce Renewed Contract, Quality Initiative
6. AspireHR Completes Phase 1 SAP HR Initiative for Shire Pharmaceuticals
7. Anthem Blue Cross and Blue Shield in New Hampshire Gives Boost to Help Small Businesses in the Granite State
8. VA Awards $3.7 Million for New Hampshire Veterans Home
9. Shires INTUNIV (Guanfacine) extended release in children with ADHD and oppositional symptoms
10. Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans
11. Shire to Present New Scientific Data on its ADHD Treatments at a National Scientific Meeting of Psychiatrists on May 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... (PRWEB) September 01, 2014 The National ... to announce that Dawn Bazarko, DNP, MPH, RN, and ... of the American Academy of Nursing. They will be ... RN-BC, CCM, FACHE, whose induction we reported last May. ... 18, 2014, during the 2014 American Academy of Nursing ...
(Date:9/1/2014)... involved in federally-filed Tylenol lawsuits ( http://www.tylenollawsuitclaims.com/ ) are ... where issues related to claims involving the pain reliever ... Bernstein Liebhard LLP reports. , According to a ... the meeting is scheduled to take place on September ... of several Tylenol conferences that have taken place this ...
(Date:9/1/2014)... Daily Gossip reveals in it's review ... that gives members access to thousands of professionally designed ... resource aims to help both people who plan on ... are looking for inspiration in creating one of a ... Now by visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Developers of FCPX ... tutorial video for the ProWorld Plugin from Pixel Film Studios. ... Pro X can do and users now have the ability ... Said Christina Austin, CEO of Pixel Film Studios. “Blurring the ... changer.” , Learn how to turn a 2D HDRI image ...
(Date:8/31/2014)... 2014 An analysis of 32 studies ... revealed a link between lower levels of Vitamin D ... the August 2014 issue of American Journal ... form of Vitamin D found in blood. , ... D lower than 9 nanograms/milliliter (ng/mL) were twice as ...
Breaking Medicine News(10 mins):Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2Health News:Pixel Film Studios Released a New Tutorial Entitled ProWorld Lesson Exclusively for Final Cut Pro X 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 3Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 4
... ... recorder prior to offering them to the public. , ... Austin, Texas (PRWEB) June 9, 2009 -- An Olympus digital ... professionals and everyday consumers. Recorders.com, the leading supplier of Olympus digital voice recorders in ...
... has proved surprisingly effective at binding to the DNA of ... minutes. The DNA binding properties of the compound were first ... Warwick by Professor Mike Hannon and Professor Alison Rodger (Professor ... the strength of its antibiotic powers have now made it ...
... Widely Expressed on Tumors and Tumor Blood Vessel Cells ... Inc., a subsidiary of Eisai Corporation of North America, ... cleared its investigational new drug (IND) application to study ... MORAb-004 targets endosialin, a protein expressed on cells associated ...
... Will Increase by a Modest $300 Million From 2008 to ... , WALTHAM, Mass., June 9 Decision Resources, one ... and healthcare issues, finds that growth in the Parkinson,s disease ... through 2018, will be offset by generic erosion of key ...
... in Four Locations to Hold Discussions on Aging in Place ... , WASHINGTON, June 9 As part of a ... in America will be hosting workshops throughout the month of ... older Americans remain in their communities. , , ...
... America, Inc. (OTC Bulletin Board: CPCF), announced today that its ... application to the MedClose(TM) Vascular Closure System (VCS) -- previously ... and basis for its new strategic plan as a Closure ... and testing of the MedClose(TM) VCS, which is an internal ...
Cached Medicine News:Health News:All Olympus Digital Voice Recorder Models Reviewed at Recorders.com 2Health News:All Olympus Digital Voice Recorder Models Reviewed at Recorders.com 3Health News:New antibiotics could come from a DNA binding compound that kills bacteria in 2 minutes 2Health News:Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors 2Health News:Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors 3Health News:Growth in the Parkinson's Disease Drug Market, Fueled by the Launch of Several New Therapies, Will be Offset by Generic Erosion of Key Agents 2Health News:How Prepared are America's Communities to Handle the Aging Boom? 2Health News:How Prepared are America's Communities to Handle the Aging Boom? 3Health News:How Prepared are America's Communities to Handle the Aging Boom? 4Health News:CPC Strengthens Foundation as a Closure Products Company with its Vertically Integrated Product Pipeline 2Health News:CPC Strengthens Foundation as a Closure Products Company with its Vertically Integrated Product Pipeline 3Health News:CPC Strengthens Foundation as a Closure Products Company with its Vertically Integrated Product Pipeline 4
(Date:9/1/2014)... Sept. 1, 2014 Reportlinker.com announces that ... its catalogue:  Drug Discovery Technologies - A ... http://www.reportlinker.com/p02349116/Drug-Discovery-Technologies---A-Global-Market-Overview.html The development of new ... requires extensive expenditure, in addition to consuming a ... a new drug involves the utilizing high-throughput screening ...
(Date:9/1/2014)... Research and Markets has announced the addition ... Disease: A Comprehensive Analysis and Market Study of New ... This report is a comprehensive analysis ... minimally-invasive biomarkers in Alzheimer,s disease, which have been ,functionally ... AD drug pipeline, and applicable commercial AD diagnostics. ...
(Date:8/30/2014)...   Royal Philips  (NYSE: PHG, AEX: PHIA) today ... ultrasound system designed to enable global hospitals and health ... and cost pressures. Making its debut at the  European ... Barcelona this week, Affiniti provides innovative technology ... resources deliver high quality patient care. ...
Breaking Medicine Technology:Drug Discovery Technologies - A Global Market Overview 2Drug Discovery Technologies - A Global Market Overview 3Drug Discovery Technologies - A Global Market Overview 4Drug Discovery Technologies - A Global Market Overview 5Drug Discovery Technologies - A Global Market Overview 6Drug Discovery Technologies - A Global Market Overview 7Drug Discovery Technologies - A Global Market Overview 8Drug Discovery Technologies - A Global Market Overview 9Drug Discovery Technologies - A Global Market Overview 10Drug Discovery Technologies - A Global Market Overview 11Drug Discovery Technologies - A Global Market Overview 12Drug Discovery Technologies - A Global Market Overview 13Drug Discovery Technologies - A Global Market Overview 14Early-Stage Minimally-Invasive Biomarkers in Alzheimer's Disease: A Comprehensive Analysis and Market Study of New Developments and Opportunities, 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4
... 16, 2007 - Somanta,Pharmaceuticals (OTCBB:SMPM) today announced ... presented later today at the American,Association for ... The poster presentation is entitled "Cytotoxicity of ... Excision,Repair and DNA Mismatch Repair defects," and ...
... Second Half of 2007 -, BRISBANE, Australia, April ... the final stage 1,results of its Phase 2 ... surgical removal of liver cancer. The 48 week,data ... improvement in,disease-free rate, the primary endpoint, of 25 ...
Cached Medicine Technology:Somanta Announces the Presentation of Alchemix Data at The American,Association for Cancer Research Annual Meeting 2Progen's Phase 2 Liver Cancer Trial Exceeds Efficacy Objective 2Progen's Phase 2 Liver Cancer Trial Exceeds Efficacy Objective 3
This compression garment can be used for Breast Augmentation, Augmentation Mammaplasty, Trans Umbilical Breast Augmentation, Transaxillary Submuscular Augmentation....
Bra With Cups...
Bras and Breast Support...
Constructed from soft Shur-grip foam and velcro closure for easy application and - reapplication...
Medicine Products: